Evidence map›Paper›PMID 35851545›Full record

Trial reportPharmaceutical statistics2023

A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint.

Yun Qing, Peter F Thall, Ying Yuan

Abstract readClinical Trial, Phase II
In one paragraph

Trial report in Pharmaceutical statistics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yun QingDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Peter F ThallDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-7293-529X
Ying YuanDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0003-3163-480X

Funding

Tropism Enhanced Oncolytic Adenovirus for the Treatment of Brain TumorsP50CA127001 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Juan Fueyo · 2008 to 2026
$41.2M
Project 3: Inhibiting Oxidative Phosphorylation in Pancreatic CancerP50CA221707 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOPETZ, SCOTT, MAITRA, ANIRBAN · 2019 to 2023
$11.0M
Bayesian Methods for Complex Precision Biotherapy Trials in OncologyR01CA261978 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIN, RUITAO, THALL, PETER F · 2021 to 2024
$1.4M
NCI NIH HHS P50 CA127001NCI NIH HHS P50 CA221707NCI NIH HHS R01 CA261978
6 · The paper itself

Abstract

A robust Bayesian design is presented for a single-arm phase II trial with an early stopping rule to monitor a time to event endpoint. The assumed model is a piecewise exponential distribution with non-informative gamma priors on the hazard parameters in subintervals of a fixed follow up interval. As an additional comparator, we also define and evaluate a version of the design based on an assumed Weibull distribution. Except for the assumed models, the piecewise exponential and Weibull model based designs are identical to an established design that assumes an exponential event time distribution with an inverse gamma prior on the mean event time. The three designs are compared by simulation under several log-logistic and Weibull distributions having different shape parameters, and for different monitoring schedules. The simulations show that, compared to the exponential inverse gamma model based design, the piecewise exponential design has substantially better performance, with much higher probabilities of correctly stopping the trial early, and shorter and less variable trial duration, when the assumed median event time is unacceptably low. Compared to the Weibull model based design, the piecewise exponential design does a much better job of maintaining small incorrect stopping probabilities in cases where the true median survival time is desirably large.

Indexed as

Research DesignBayes TheoremComputer SimulationHumansProbabilityBayesian adaptive designfutility monitoringgo/no-go decisioninterim analysis

Identifiers

PMID35851545
PMCPMC10150550

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.